Serenex Announces Issuance of European Patent for Oral Mucositis Product SNX-1012

DURHAM, NC -- (MARKET WIRE) -- March 20, 2007 -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today the issuance of a patent covering methods of treating or preventing mucositis by the European Patent Office ("EPO"). The patent, EP 212050B1, covers a broad class of compounds in various formulations that may treat mucositis of multiple mucosal surfaces.

Back to news